Development of the Diabetes Technology Society Blood Glucose Monitor System Surveillance Protocol

David C. Klonoff, Courtney Lias, Stayce Beck, Joan Lee Parkes, Boris Kovatchev, Robert A. Vigersky, Guillermo Arreaza-Rubin, Robert D. Burk, Aaron Kowalski, Randie Little, James Nichols, Matt Petersen, Kelly Rawlings, David B. Sacks, Eric Sampson, Steve Scott, Jane Jeffrie Seley, Robbert Slingerland, Hubert W. Vesper

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Background: Inaccurate blood glucsoe monitoring systems (BGMSs) can lead to adverse health effects. The Diabetes Technology Society (DTS) Surveillance Program for cleared BGMSs is intended to protect people with diabetes from inaccurate, unreliable BGMS products that are currently on the market in the United States. The Surveillance Program will provide an independent assessment of the analytical performance of cleared BGMSs. Methods: The DTS BGMS Surveillance Program Steering Committee included experts in glucose monitoring, surveillance testing, and regulatory science. Over one year, the committee engaged in meetings and teleconferences aiming to describe how to conduct BGMS surveillance studies in a scientifically sound manner that is in compliance with good clinical practice and all relevant regulations. Results: A clinical surveillance protocol was created that contains performance targets and analytical accuracy-testing studies with marketed BGMS products conducted by qualified clinical and laboratory sites. This protocol entitled "Protocol for the Diabetes Technology Society Blood Glucose Monitor System Surveillance Program" is attached as supplementary material. Conclusion: This program is needed because currently once a BGMS product has been cleared for use by the FDA, no systematic postmarket Surveillance Program exists that can monitor analytical performance and detect potential problems. This protocol will allow identification of inaccurate and unreliable BGMSs currently available on the US market. The DTS Surveillance Program will provide BGMS manufacturers a benchmark to understand the postmarket analytical performance of their products. Furthermore, patients, health care professionals, payers, and regulatory agencies will be able to use the results of the study to make informed decisions to, respectively, select, prescribe, finance, and regulate BGMSs on the market.

Original languageEnglish (US)
Pages (from-to)697-707
Number of pages11
JournalJournal of diabetes science and technology
Volume10
Issue number3
DOIs
StatePublished - May 1 2016

Fingerprint

Medical problems
Glucose
Blood Glucose
Blood
Technology
Monitoring
Telecommunications
Benchmarking
Clinical Protocols
Testing
Finance
Health care
Patient Care
Delivery of Health Care
Health
Acoustic waves

Keywords

  • accuracy
  • blood glucose monitor
  • FDA
  • meter
  • protocol
  • surveillance

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Bioengineering
  • Medicine(all)
  • Biomedical Engineering

Cite this

Klonoff, D. C., Lias, C., Beck, S., Parkes, J. L., Kovatchev, B., Vigersky, R. A., ... Vesper, H. W. (2016). Development of the Diabetes Technology Society Blood Glucose Monitor System Surveillance Protocol. Journal of diabetes science and technology, 10(3), 697-707. https://doi.org/10.1177/1932296815614587

Development of the Diabetes Technology Society Blood Glucose Monitor System Surveillance Protocol. / Klonoff, David C.; Lias, Courtney; Beck, Stayce; Parkes, Joan Lee; Kovatchev, Boris; Vigersky, Robert A.; Arreaza-Rubin, Guillermo; Burk, Robert D.; Kowalski, Aaron; Little, Randie; Nichols, James; Petersen, Matt; Rawlings, Kelly; Sacks, David B.; Sampson, Eric; Scott, Steve; Seley, Jane Jeffrie; Slingerland, Robbert; Vesper, Hubert W.

In: Journal of diabetes science and technology, Vol. 10, No. 3, 01.05.2016, p. 697-707.

Research output: Contribution to journalArticle

Klonoff, DC, Lias, C, Beck, S, Parkes, JL, Kovatchev, B, Vigersky, RA, Arreaza-Rubin, G, Burk, RD, Kowalski, A, Little, R, Nichols, J, Petersen, M, Rawlings, K, Sacks, DB, Sampson, E, Scott, S, Seley, JJ, Slingerland, R & Vesper, HW 2016, 'Development of the Diabetes Technology Society Blood Glucose Monitor System Surveillance Protocol', Journal of diabetes science and technology, vol. 10, no. 3, pp. 697-707. https://doi.org/10.1177/1932296815614587
Klonoff, David C. ; Lias, Courtney ; Beck, Stayce ; Parkes, Joan Lee ; Kovatchev, Boris ; Vigersky, Robert A. ; Arreaza-Rubin, Guillermo ; Burk, Robert D. ; Kowalski, Aaron ; Little, Randie ; Nichols, James ; Petersen, Matt ; Rawlings, Kelly ; Sacks, David B. ; Sampson, Eric ; Scott, Steve ; Seley, Jane Jeffrie ; Slingerland, Robbert ; Vesper, Hubert W. / Development of the Diabetes Technology Society Blood Glucose Monitor System Surveillance Protocol. In: Journal of diabetes science and technology. 2016 ; Vol. 10, No. 3. pp. 697-707.
@article{26438f6fc85742a3bc0f7472c909441b,
title = "Development of the Diabetes Technology Society Blood Glucose Monitor System Surveillance Protocol",
abstract = "Background: Inaccurate blood glucsoe monitoring systems (BGMSs) can lead to adverse health effects. The Diabetes Technology Society (DTS) Surveillance Program for cleared BGMSs is intended to protect people with diabetes from inaccurate, unreliable BGMS products that are currently on the market in the United States. The Surveillance Program will provide an independent assessment of the analytical performance of cleared BGMSs. Methods: The DTS BGMS Surveillance Program Steering Committee included experts in glucose monitoring, surveillance testing, and regulatory science. Over one year, the committee engaged in meetings and teleconferences aiming to describe how to conduct BGMS surveillance studies in a scientifically sound manner that is in compliance with good clinical practice and all relevant regulations. Results: A clinical surveillance protocol was created that contains performance targets and analytical accuracy-testing studies with marketed BGMS products conducted by qualified clinical and laboratory sites. This protocol entitled {"}Protocol for the Diabetes Technology Society Blood Glucose Monitor System Surveillance Program{"} is attached as supplementary material. Conclusion: This program is needed because currently once a BGMS product has been cleared for use by the FDA, no systematic postmarket Surveillance Program exists that can monitor analytical performance and detect potential problems. This protocol will allow identification of inaccurate and unreliable BGMSs currently available on the US market. The DTS Surveillance Program will provide BGMS manufacturers a benchmark to understand the postmarket analytical performance of their products. Furthermore, patients, health care professionals, payers, and regulatory agencies will be able to use the results of the study to make informed decisions to, respectively, select, prescribe, finance, and regulate BGMSs on the market.",
keywords = "accuracy, blood glucose monitor, FDA, meter, protocol, surveillance",
author = "Klonoff, {David C.} and Courtney Lias and Stayce Beck and Parkes, {Joan Lee} and Boris Kovatchev and Vigersky, {Robert A.} and Guillermo Arreaza-Rubin and Burk, {Robert D.} and Aaron Kowalski and Randie Little and James Nichols and Matt Petersen and Kelly Rawlings and Sacks, {David B.} and Eric Sampson and Steve Scott and Seley, {Jane Jeffrie} and Robbert Slingerland and Vesper, {Hubert W.}",
year = "2016",
month = "5",
day = "1",
doi = "10.1177/1932296815614587",
language = "English (US)",
volume = "10",
pages = "697--707",
journal = "Journal of diabetes science and technology",
issn = "1932-2968",
publisher = "Diabetes Technology Society",
number = "3",

}

TY - JOUR

T1 - Development of the Diabetes Technology Society Blood Glucose Monitor System Surveillance Protocol

AU - Klonoff, David C.

AU - Lias, Courtney

AU - Beck, Stayce

AU - Parkes, Joan Lee

AU - Kovatchev, Boris

AU - Vigersky, Robert A.

AU - Arreaza-Rubin, Guillermo

AU - Burk, Robert D.

AU - Kowalski, Aaron

AU - Little, Randie

AU - Nichols, James

AU - Petersen, Matt

AU - Rawlings, Kelly

AU - Sacks, David B.

AU - Sampson, Eric

AU - Scott, Steve

AU - Seley, Jane Jeffrie

AU - Slingerland, Robbert

AU - Vesper, Hubert W.

PY - 2016/5/1

Y1 - 2016/5/1

N2 - Background: Inaccurate blood glucsoe monitoring systems (BGMSs) can lead to adverse health effects. The Diabetes Technology Society (DTS) Surveillance Program for cleared BGMSs is intended to protect people with diabetes from inaccurate, unreliable BGMS products that are currently on the market in the United States. The Surveillance Program will provide an independent assessment of the analytical performance of cleared BGMSs. Methods: The DTS BGMS Surveillance Program Steering Committee included experts in glucose monitoring, surveillance testing, and regulatory science. Over one year, the committee engaged in meetings and teleconferences aiming to describe how to conduct BGMS surveillance studies in a scientifically sound manner that is in compliance with good clinical practice and all relevant regulations. Results: A clinical surveillance protocol was created that contains performance targets and analytical accuracy-testing studies with marketed BGMS products conducted by qualified clinical and laboratory sites. This protocol entitled "Protocol for the Diabetes Technology Society Blood Glucose Monitor System Surveillance Program" is attached as supplementary material. Conclusion: This program is needed because currently once a BGMS product has been cleared for use by the FDA, no systematic postmarket Surveillance Program exists that can monitor analytical performance and detect potential problems. This protocol will allow identification of inaccurate and unreliable BGMSs currently available on the US market. The DTS Surveillance Program will provide BGMS manufacturers a benchmark to understand the postmarket analytical performance of their products. Furthermore, patients, health care professionals, payers, and regulatory agencies will be able to use the results of the study to make informed decisions to, respectively, select, prescribe, finance, and regulate BGMSs on the market.

AB - Background: Inaccurate blood glucsoe monitoring systems (BGMSs) can lead to adverse health effects. The Diabetes Technology Society (DTS) Surveillance Program for cleared BGMSs is intended to protect people with diabetes from inaccurate, unreliable BGMS products that are currently on the market in the United States. The Surveillance Program will provide an independent assessment of the analytical performance of cleared BGMSs. Methods: The DTS BGMS Surveillance Program Steering Committee included experts in glucose monitoring, surveillance testing, and regulatory science. Over one year, the committee engaged in meetings and teleconferences aiming to describe how to conduct BGMS surveillance studies in a scientifically sound manner that is in compliance with good clinical practice and all relevant regulations. Results: A clinical surveillance protocol was created that contains performance targets and analytical accuracy-testing studies with marketed BGMS products conducted by qualified clinical and laboratory sites. This protocol entitled "Protocol for the Diabetes Technology Society Blood Glucose Monitor System Surveillance Program" is attached as supplementary material. Conclusion: This program is needed because currently once a BGMS product has been cleared for use by the FDA, no systematic postmarket Surveillance Program exists that can monitor analytical performance and detect potential problems. This protocol will allow identification of inaccurate and unreliable BGMSs currently available on the US market. The DTS Surveillance Program will provide BGMS manufacturers a benchmark to understand the postmarket analytical performance of their products. Furthermore, patients, health care professionals, payers, and regulatory agencies will be able to use the results of the study to make informed decisions to, respectively, select, prescribe, finance, and regulate BGMSs on the market.

KW - accuracy

KW - blood glucose monitor

KW - FDA

KW - meter

KW - protocol

KW - surveillance

UR - http://www.scopus.com/inward/record.url?scp=85009484121&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85009484121&partnerID=8YFLogxK

U2 - 10.1177/1932296815614587

DO - 10.1177/1932296815614587

M3 - Article

C2 - 26481642

AN - SCOPUS:85009484121

VL - 10

SP - 697

EP - 707

JO - Journal of diabetes science and technology

JF - Journal of diabetes science and technology

SN - 1932-2968

IS - 3

ER -